Immune checkpoint inhibitors are monoclonal antibodies directed against cellular pathways on T-cells to treat different types of malignancies. This new therapy can cause immune-related adverse events that can involve almost any organ system. This article will review clinical presentations, molecular mechanisms and imaging manifestations of adverse events caused by checkpoint inhibitors and also illustrate the pseudoprogression tumor response pattern
Immune checkpoint inhibitors have recently emerged as an exciting new treatment paradigm across a br...
Immune checkpoint inhibitors have recently emerged as an exciting new treatment paradigm across a br...
The introduction into clinical practice of immune checkpoint inhibitors that block cytotoxic T-lymph...
Immunotherapy with checkpoint inhibitors (ICIs) is becoming standard of practice for an increasing n...
In recent years, a wide range of cancer immunotherapies have been developed and have become increasi...
Manipulating an individual's immune system through immune checkpoint blockade is revolutionizing the...
Therapy and prognosis of several solid and hematologic malignancies, including non-small cell lung c...
Immune checkpoint inhibition with monoclonal antibodies is becoming increasingly commonplace in canc...
The immunotherapy revolution in cancer treatment involves a variety of specialists, not only oncolog...
Immunotherapies comprise of a class of cancer therapies that are increasingly used for treatment of ...
Purpose: Cancer treatments with immune checkpoint inhibitors (ICI) are associated with a unique set ...
Immune checkpoint blockade (CPB) utilizing such agents as ipilimumab, nivolumab, or pembrolizumab ha...
Jennifer M Yoest Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, ...
OBJECTIVE: Monoclonal antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4) used for treatmen...
Three checkpoint inhibitor drugs have been approved by the US Food and Drug Administration for use i...
Immune checkpoint inhibitors have recently emerged as an exciting new treatment paradigm across a br...
Immune checkpoint inhibitors have recently emerged as an exciting new treatment paradigm across a br...
The introduction into clinical practice of immune checkpoint inhibitors that block cytotoxic T-lymph...
Immunotherapy with checkpoint inhibitors (ICIs) is becoming standard of practice for an increasing n...
In recent years, a wide range of cancer immunotherapies have been developed and have become increasi...
Manipulating an individual's immune system through immune checkpoint blockade is revolutionizing the...
Therapy and prognosis of several solid and hematologic malignancies, including non-small cell lung c...
Immune checkpoint inhibition with monoclonal antibodies is becoming increasingly commonplace in canc...
The immunotherapy revolution in cancer treatment involves a variety of specialists, not only oncolog...
Immunotherapies comprise of a class of cancer therapies that are increasingly used for treatment of ...
Purpose: Cancer treatments with immune checkpoint inhibitors (ICI) are associated with a unique set ...
Immune checkpoint blockade (CPB) utilizing such agents as ipilimumab, nivolumab, or pembrolizumab ha...
Jennifer M Yoest Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, ...
OBJECTIVE: Monoclonal antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4) used for treatmen...
Three checkpoint inhibitor drugs have been approved by the US Food and Drug Administration for use i...
Immune checkpoint inhibitors have recently emerged as an exciting new treatment paradigm across a br...
Immune checkpoint inhibitors have recently emerged as an exciting new treatment paradigm across a br...
The introduction into clinical practice of immune checkpoint inhibitors that block cytotoxic T-lymph...